Pharming Group NV (PHAR) News

Pharming Group NV (PHAR): $8.60

0.29 (+3.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PHAR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

Filter PHAR News Items

PHAR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PHAR News Highlights

  • For PHAR, its 30 day story count is now at 5.
  • Over the past 14 days, the trend for PHAR's stories per day has been choppy and unclear. It has oscillated between 1 and 4.

Latest PHAR News From Around the Web

Below are the latest news stories about Pharming Group NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.

Pharming receives positive EMA decision on paediatric investigation plan (PIP) for leniolisib in Europe

Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that a positive decision has been made by the European Medicines Agency (EMA) on the Paediatric Investigation Plan (PIP) for leniolisib, a phosphoinositide 3-kinase (PI3K) inhibitor, currently in development for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS).

Yahoo | January 6, 2022

Pharming Group N.V.: Pharming Group and Sanofi renew strategic manufacturing partnership agreement

The company extends its existing 11-year partnership with Sanofi with an additional 5 years The company will no longer pursue the realization of its downstream production facility and will be savi

FinanzNachrichten | December 23, 2021

Pharming Group and Sanofi renew strategic manufacturing partnership agreement

Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that it has renewed its strategic manufacturing partnership with long-term manufacturing partner Sanofi S.A. The extended 5-year contract which includes options for extensions, ensures the continuation of the downstream processing in the production of RUCONEST®, a recombinant C1 inhibitor product approved for the acute treatment of hereditary angioedema.

Yahoo | December 23, 2021

Pharming Group (NASDAQ:PHAR) Sees Significant Decline in Short Interest

Pharming Group (NASDAQ:PHAR) was the target of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 4,900 shares, a drop of 38.0% from the November 15th total of 7,900 shares. Based on an average trading volume of 8,900 shares, the days-to-cover ratio is presently […]

Transcript Daily | December 17, 2021

Zacks Investment Research Lowers Pharming Group (NASDAQ:PHAR) to Hold

Zacks Investment Research downgraded shares of Pharming Group (NASDAQ:PHAR) from a buy rating to a hold rating in a research report sent to investors on Friday morning, Zacks.com reports. According to Zacks, Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement therapies and precision medicines for the treatment of []

Dakota Financial News | December 13, 2021

Zacks Investment Research Upgrades Pharming Group (NASDAQ:PHAR) to Buy

Pharming Group (NASDAQ:PHAR) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Tuesday, Zacks.com reports. The brokerage currently has a $8.50 target price on the stock. Zacks Investment Researchs price target indicates a potential upside of 7.53% from the stocks current price. According []

Dakota Financial News | December 7, 2021

Pharming Group (NASDAQ:PHAR) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Pharming Group (NASDAQ:PHAR) from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. They currently have $9.00 price objective on the stock. According to Zacks, Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement []

Dakota Financial News | December 4, 2021

Zacks Investment Research Downgrades Pharming Group (NASDAQ:PHAR) to Hold

Pharming Group (NASDAQ:PHAR) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Monday, Zacks.com reports. According to Zacks, Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement therapies and precision medicines for the treatment []

Dakota Financial News | December 1, 2021

Pharming Group (OTCMKTS:PHGUF) Lifted to Hold at Zacks Investment Research

Pharming Group (OTCMKTS:PHGUF) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued on Saturday, Zacks.com reports. According to Zacks, Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company []

Dakota Financial News | November 15, 2021

Pharming Group (NASDAQ:PHAR) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Pharming Group (NASDAQ:PHAR) from a hold rating to a buy rating in a research note released on Wednesday morning, Zacks.com reports. The firm currently has $10.00 price target on the stock. According to Zacks, Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement []

Transcript Daily | November 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.54 seconds.